<![CDATA[Pharma — Marts 2023]]>Merck Stock Looks Better Priced Compared To Its Sector Peer https://www.proinvestor.com/investornyt/948162/merck-stock-looks-better-priced-compared-to-its-sector-peer

]]>https://dev.proinvestor.com/forum/topic/400872/pharma-marts-2023RSS for NodeSun, 07 Jun 2026 07:52:41 GMTWed, 01 Mar 2023 05:12:39 GMT60<![CDATA[Reply to Pharma — Marts 2023 on Mon, 27 Mar 2023 12:20:49 GMT]]>Nå, linket lader sig ikke copypaste https://investors.biontech.de/node/14871/pdf

]]>https://dev.proinvestor.com/forum/post/8037708https://dev.proinvestor.com/forum/post/8037708Mon, 27 Mar 2023 12:20:49 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 27 Mar 2023 12:19:40 GMT]]>BioNTech årsregnskab (link) 243 mio aktier kurs 113 €, MCAP 27.5 mia. Cash 13,9 mia

]]>https://dev.proinvestor.com/forum/post/8037706https://dev.proinvestor.com/forum/post/8037706Mon, 27 Mar 2023 12:19:40 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 27 Mar 2023 07:54:35 GMT]]>Novartis stiger oven på lovende kræftstudie
27.3.2023 09.10 • MarketWire •
Novartis har fået en god start på børshandlen mandag, efter at medicinalkoncernen har præsenteret lovende resultater fra et studie med kræftmidlet Kisqali.

Det rapporterer Bloomberg News.

Kisqali er i forvejen godkendt til behandling af brystkræft, og det nye studie viser, at midlet antyder, at det også reducerer risikoen for, at brystkræften vender tilbage.

Aktien i Novartis stiger fra åbningen med omkring 5 pct.

.\

]]>https://dev.proinvestor.com/forum/post/8037703https://dev.proinvestor.com/forum/post/8037703Mon, 27 Mar 2023 07:54:35 GMT<![CDATA[Reply to Pharma — Marts 2023 on Thu, 23 Mar 2023 14:03:10 GMT]]>Sanofi og Regeneron stiger 6-7%.Forsøg viser god virkning af Dupixent mod KOL. https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-demonstrates-potential-become-first-biologic

]]>https://dev.proinvestor.com/forum/post/8037709https://dev.proinvestor.com/forum/post/8037709Thu, 23 Mar 2023 14:03:10 GMT<![CDATA[Reply to Pharma — Marts 2023 on Tue, 21 Mar 2023 07:24:35 GMT]]>Sanofi : EU Approves Dupixent To Treat Severe Atopic Dermatitis In Children https://www.proinvestor.com/investornyt/957400/sanofi-eu-approves-dupixent-to-treat-severe-atopic-dermatitis-in-children

]]>https://dev.proinvestor.com/forum/post/8037704https://dev.proinvestor.com/forum/post/8037704Tue, 21 Mar 2023 07:24:35 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 20 Mar 2023 11:00:21 GMT]]>Is Roche a Buy Now? https://www.proinvestor.com/investornyt/956954/is-roche-a-buy-now

]]>https://dev.proinvestor.com/forum/post/8037707https://dev.proinvestor.com/forum/post/8037707Mon, 20 Mar 2023 11:00:21 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 20 Mar 2023 05:57:14 GMT]]>Roche : New Data For Evrysdi Reinforce Long-Term Efficacy And Safety Profile In Types 2 And 3 SMA https://www.proinvestor.com/investornyt/956868/roche-new-data-for-evrysdi-reinforce-long-term-efficacy-and-safety-profile-in-types-2-and-3-sma

]]>https://dev.proinvestor.com/forum/post/8037700https://dev.proinvestor.com/forum/post/8037700Mon, 20 Mar 2023 05:57:14 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 20 Mar 2023 04:46:31 GMT]]>Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing https://www.proinvestor.com/investornyt/956850/novartis-sma-drug-zolgensma-long-term-data-shows-sustained-durability-up-to-75-years-post-dosing

]]>https://dev.proinvestor.com/forum/post/8037702https://dev.proinvestor.com/forum/post/8037702Mon, 20 Mar 2023 04:46:31 GMT<![CDATA[Reply to Pharma — Marts 2023 on Sat, 18 Mar 2023 12:36:03 GMT]]>Ready to Buy the Dip? Johnson & Johnson Stock Is a Smart Buy
https://www.proinvestor.com/investornyt/956635/ready-to-buy-the-dip-johnson-amp-johnson-stock-is-a-smart-buy

]]>https://dev.proinvestor.com/forum/post/8037705https://dev.proinvestor.com/forum/post/8037705Sat, 18 Mar 2023 12:36:03 GMT<![CDATA[Reply to Pharma — Marts 2023 on Sat, 18 Mar 2023 12:32:45 GMT]]>Could This Be Merck's Next Blockbuster
Drug? https://www.proinvestor.com/investornyt/956634/could-this-be-mercks-next-blockbuster-drug

]]>https://dev.proinvestor.com/forum/post/8037701https://dev.proinvestor.com/forum/post/8037701Sat, 18 Mar 2023 12:32:45 GMT<![CDATA[Reply to Pharma — Marts 2023 on Sat, 18 Mar 2023 06:14:38 GMT]]>Pfizer Stock (NYSE:PFE): Exceptional Value Near 52-Week Lows
https://www.proinvestor.com/investornyt/956590/pfizer-stock-nysepfe-exceptional-value-near-52-week-lows

]]>https://dev.proinvestor.com/forum/post/8037694https://dev.proinvestor.com/forum/post/8037694Sat, 18 Mar 2023 06:14:38 GMT<![CDATA[Reply to Pharma — Marts 2023 on Tue, 14 Mar 2023 07:02:03 GMT]]>Så købte Pfizer Seagen for 43 mia usd.En af fordelene ved at være stor. Der er ikke ret mange andre, som ville have råd til det.

]]>https://dev.proinvestor.com/forum/post/8037698https://dev.proinvestor.com/forum/post/8037698Tue, 14 Mar 2023 07:02:03 GMT<![CDATA[Reply to Pharma — Marts 2023 on Thu, 09 Mar 2023 04:51:42 GMT]]>Dagens aviser med Novo Nordisk, KBHL og Ørsted https://www.proinvestor.com/investornyt/952022/torsdagens-aviser-med-novo-nordisk-kbhl-og-orsted

]]>https://dev.proinvestor.com/forum/post/8037699https://dev.proinvestor.com/forum/post/8037699Thu, 09 Mar 2023 04:51:42 GMT<![CDATA[Reply to Pharma — Marts 2023 on Thu, 09 Mar 2023 04:50:35 GMT]]>Asien: Blandet udviking grundet fravær af indikationer fra USA https://www.proinvestor.com/investornyt/952023/asien-blandet-udviking-grundet-fravaer-af-indikationer-fra-usa

]]>https://dev.proinvestor.com/forum/post/8037710https://dev.proinvestor.com/forum/post/8037710Thu, 09 Mar 2023 04:50:35 GMT<![CDATA[Reply to Pharma — Marts 2023 on Thu, 09 Mar 2023 04:49:18 GMT]]>Lilly's Solanezumab Fails In Alzheimer's
Prevention Trial https://www.proinvestor.com/investornyt/951996/lillys-solanezumab-fails-in-alzheimers-prevention-trial

]]>https://dev.proinvestor.com/forum/post/8037695https://dev.proinvestor.com/forum/post/8037695Thu, 09 Mar 2023 04:49:18 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 06 Mar 2023 11:56:50 GMT]]>Sanofi Could Be on a Roll With a Strong
Performance and Its Latest FDA Approval https://www.proinvestor.com/investornyt/950455/sanofi-could-be-on-a-roll-with-a-strong-performance-and-its-latest-fda-approval

]]>https://dev.proinvestor.com/forum/post/8037697https://dev.proinvestor.com/forum/post/8037697Mon, 06 Mar 2023 11:56:50 GMT<![CDATA[Reply to Pharma — Marts 2023 on Mon, 06 Mar 2023 07:39:25 GMT]]>AstraZeneca: Enhertu DESTINY-
PanTumor02 Shows Positive Results https://www.proinvestor.com/investornyt/950389/astrazeneca-enhertu-destiny-pantumor02-shows-positive-results

]]>https://dev.proinvestor.com/forum/post/8037696https://dev.proinvestor.com/forum/post/8037696Mon, 06 Mar 2023 07:39:25 GMT<![CDATA[Reply to Pharma — Marts 2023 on Thu, 02 Mar 2023 06:15:02 GMT]]>Merck KgaA FY22 Profit Rises, Lifts
Dividend; Sees Organic Sales Growth In FY23; Backs FY25 View https://www.proinvestor.com/investornyt/948875/merck-kgaa-fy22-profit-rises-lifts-dividend-sees-organic-sales-growth-in-fy23-backs-fy25-view

]]>https://dev.proinvestor.com/forum/post/8037693https://dev.proinvestor.com/forum/post/8037693Thu, 02 Mar 2023 06:15:02 GMT